drugset / Trial / NCT00916461

Summary

The purpose of this study is to determine whether the addition of minocycline or placebo to treatment as usual (TAU): 1. prevents the accumulation of negative symptoms and intellectual decline following a first episode of non-affective psychosis; and 2. whether minocycline stabilizes the efficacy of antipsychotics.

Timeline

Start
2006-05
Primary completion
2008-03
Completion
2008-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Minocycline Small molecule 200 mg Oral

Indications